Kiyohiro Nishikawa

5PUBLICATIONS
10CO-AUTHORS
Predictive and prognostic markersNanomedicineApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Rheumatology and arthritisImmunology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 08, 2025
Prospective Cohort Study of Trastuzumab Biosimilar CT-P6 in HER2-Positive Gastric Cancer: Japanese Real-World Outcomes.

Hiroya Taniguchi, Kiyohiro Nishikawa, Tatsuo Haneji

|Sep 12, 2023
Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies.

Tsutomu Takeuchi, Kiyohiro Nishikawa, Fumika Yamada

|Jul 08, 2022
Safety, efficacy, and drug survival of the infliximab biosimilar CT-P13 in post-marketing surveillance of Japanese patients with psoriasis.

Akimichi Morita, Kiyohiro Nishikawa, Fumika Yamada

|Dec 17, 2021
Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics.

Tsutomu Takeuchi, Kiyohiro Nishikawa, Fumika Yamada

|Jan 15, 2021
Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan.

Shintaro Sagami, Kiyohiro Nishikawa, Fumika Yamada

Pageof 1

Frequent Collaborators

1 joint publications

Shintaro Sagami

1 joint publications

Fumika Yamada

1 joint publications

Mamoru Watanabe

1 joint publications

Toshifumi Hibi